Business Problem: Complex operational issues related providing ongoing customer support for novel insulin pump while protecting product price point Solution: Develop extended warranty program that ensures ongoing customer acceptance, public payer and regulatory compliance. Outcome: Solution proposed that protected product pricing, blunted competitive…
Business Problem: Early state molecular diagnostic start-up required go to market plan to secure early stage angel funding. Solution: Development of business plan focused generating clinical trial revenue to support ongoing clinical validation of technology. Leveraging key opinion leader support…
Business Problem: Restricted access to TAA/AAA Endovascular Stent Grafts despite high quality clinical data for high risk patient groups. Funding for devices restricted and contracting. Solution: Encourage development of Canadian Society of Vascular Surgery position paper on issue, supported by…
Business Problem: Insulin Pumps not reimbursed by any public health system in Canada. Disparate advocacy efforts proving ineffective. Solution: Simplify reimbursement “ask”, create alignment among advocates, create inflection points focused on benefit of providing insulin pump coverage for children. Outcome: …
Business Problem: Launching a Novel High-Value Molecular Assay for the Early Identification of Colon Cancer (CRC). Company Objective: Secure lead customers, reinforce value proposition, demonstrate value of assay to secure partnership deals in international markets. Solution: Build Health Economic Argumentation…
Rna Diagnostics’s innovative RDA™ Cancer Chemotherapy Guidance Assay and Medtronic’s leading edge Symplicty™ Renal Denervation System are considered disruptive technologies and were selected as lead projects for MaRS EXCITE. GCA HealthCare Consulting has provided specialized consultancy services to both firms…
